11-824762-C-G
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBS1_Supporting
The NM_020376.4(PNPLA2):āc.1415C>Gā(p.Ala472Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000132 in 1,555,952 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_020376.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PNPLA2 | NM_020376.4 | c.1415C>G | p.Ala472Gly | missense_variant | 10/10 | ENST00000336615.9 | NP_065109.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PNPLA2 | ENST00000336615.9 | c.1415C>G | p.Ala472Gly | missense_variant | 10/10 | 1 | NM_020376.4 | ENSP00000337701.4 | ||
PNPLA2 | ENST00000529255.1 | n.845C>G | non_coding_transcript_exon_variant | 4/4 | 1 | |||||
PNPLA2 | ENST00000525250.5 | n.2269C>G | non_coding_transcript_exon_variant | 6/6 | 2 | |||||
ENSG00000255108 | ENST00000532946.1 | n.307-899G>C | intron_variant | 5 |
Frequencies
GnomAD3 genomes AF: 0.0000920 AC: 14AN: 152202Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000459 AC: 7AN: 152416Hom.: 1 AF XY: 0.0000473 AC XY: 4AN XY: 84588
GnomAD4 exome AF: 0.000136 AC: 191AN: 1403750Hom.: 0 Cov.: 42 AF XY: 0.000128 AC XY: 89AN XY: 694992
GnomAD4 genome AF: 0.0000920 AC: 14AN: 152202Hom.: 0 Cov.: 33 AF XY: 0.0000672 AC XY: 5AN XY: 74350
ClinVar
Submissions by phenotype
Neutral lipid storage myopathy Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 09, 2022 | This sequence change replaces alanine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 472 of the PNPLA2 protein (p.Ala472Gly). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with PNPLA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 465784). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 10, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | May 21, 2020 | A heterozygous missense variant was identified, NM_020376.3(PNPLA2):c.1415C>G in exon 10 of 10 of the PNPLA2 gene. This substitution is predicted to create a minor amino acid change from alanine to glycine at position 472 of the protein, NP_065109.1(PNPLA2):p.(Ala472Gly). The alanine at this position has low conservation (100 vertebrates, UCSC), but is not situated in a known functional domain. In silico software predicts this variant to be tolerated (Polyphen, SIFT, CADD, Mutation Taster). The variant is present in the gnomAD population database at a frequency of 0.005% (8 heterozygotes, 1 homozygote). This variant has been previously reported as a VUS in ClinVar. Based on information available at the time of curation, this variant has been classified as a VARIANT of UNCERTAIN SIGNIFICANCE (VUS) with LOW CLINICAL RELEVANCE. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 16, 2024 | The c.1415C>G (p.A472G) alteration is located in exon 10 (coding exon 9) of the PNPLA2 gene. This alteration results from a C to G substitution at nucleotide position 1415, causing the alanine (A) at amino acid position 472 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at